Switch theme
Sign up to access all valuation multiples
Alligator Bioscience AB is a research-based biotechnology company that develops immune activating antibody drugs for tumor-directed immunotherapy. It is engaged in the development of immunotherapies for the treatment of cancer Its products are ADC-1013, ATOR-1015, and ATOR-1016.
2000
52
LTM Revenue $6.9M
LTM EBITDA -$14.1M
$8.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alligator Bioscience has a last 12-month revenue of $6.9M and a last 12-month EBITDA of -$14.1M.
In the most recent fiscal year, Alligator Bioscience achieved revenue of $5.7M and an EBITDA of -$16.4M.
Alligator Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alligator Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.8M | $5.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$23.6M | -$16.4M | XXX | XXX | XXX |
| EBITDA Margin | -409% | -286% | XXX | XXX | XXX |
| Net Profit | -$19.2M | -$24.7M | XXX | XXX | XXX |
| Net Margin | -333% | -430% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alligator Bioscience's stock price is SEK 6 (or $1).
Alligator Bioscience has current market cap of SEK 104M (or $10.4M), and EV of SEK 83.8M (or $8.3M).
See Alligator Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.3M | $10.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alligator Bioscience has market cap of $10.4M and EV of $8.3M.
Alligator Bioscience's trades at 1.2x LTM EV/Revenue multiple, and -0.6x LTM EBITDA.
Analysts estimate Alligator Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alligator Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.3M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlligator Bioscience's NTM/LTM revenue growth is 45%
Alligator Bioscience's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Alligator Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alligator Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alligator Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -286% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -241% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 265% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 428% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alligator Bioscience acquired XXX companies to date.
Last acquisition by Alligator Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Alligator Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alligator Bioscience founded? | Alligator Bioscience was founded in 2000. |
| Where is Alligator Bioscience headquartered? | Alligator Bioscience is headquartered in Sweden. |
| How many employees does Alligator Bioscience have? | As of today, Alligator Bioscience has 52 employees. |
| Who is the CEO of Alligator Bioscience? | Alligator Bioscience's CEO is Mr. Soren Bregenholt. |
| Is Alligator Bioscience publicy listed? | Yes, Alligator Bioscience is a public company listed on STO. |
| What is the stock symbol of Alligator Bioscience? | Alligator Bioscience trades under ATORX ticker. |
| When did Alligator Bioscience go public? | Alligator Bioscience went public in 2016. |
| Who are competitors of Alligator Bioscience? | Similar companies to Alligator Bioscience include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alligator Bioscience? | Alligator Bioscience's current market cap is $10.4M |
| What is the current revenue of Alligator Bioscience? | Alligator Bioscience's last 12-month revenue is $6.9M. |
| What is the current EBITDA of Alligator Bioscience? | Alligator Bioscience's last 12-month EBITDA is -$14.1M. |
| What is the current EV/Revenue multiple of Alligator Bioscience? | Current revenue multiple of Alligator Bioscience is 1.2x. |
| What is the current EV/EBITDA multiple of Alligator Bioscience? | Current EBITDA multiple of Alligator Bioscience is -0.6x. |
| What is the current revenue growth of Alligator Bioscience? | Alligator Bioscience revenue growth between 2023 and 2024 was -1%. |
| Is Alligator Bioscience profitable? | Yes, Alligator Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
